Scilex Holding Co
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
SCLX$1.61-7.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(24,377) | $(30,753) |
| Adjustments to reconcile net loss to net cash proceeds from (used for) operating activities: | ||
| Depreciation and amortization | 1,031 | 1,037 |
| Amortization of debt issuance costs and debt discount | 31 | — |
| Non-cash operating lease cost | 180 | 144 |
| Stock-based compensation | 3,558 | 3,720 |
| Loss on derivative liability | 457 | 5,253 |
| Allocated expenses for warrant issuance cost | 1,375 | — |
| Change in fair value of debt and liability instruments | 3,905 | — |
| Other | 26 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivables, net | 4,881 | 1,992 |
| Inventory | 726 | (897) |
| Prepaid expenses and other | (39) | 294 |
| Other long-term assets | (30) | 997 |
| Accounts payable | 1,265 | 2,001 |
| Accrued payroll | 1,046 | 359 |
| Accrued expenses | 1,120 | 3,543 |
| Accrued rebates and fees | 14,430 | 4,736 |
| Other liabilities | (197) | (175) |
| Other long-term liabilities | 3 | 5 |
| Net cash proceeds from (used for) operating activities | 9,391 | (7,744) |
| Investing activities | ||
| Acquisition consideration paid in cash for Romeg intangible asset acquisition | (150) | — |
| Net cash used for investing activities | (150) | — |
| Financing activities | ||
| Proceeds from issuance of shares under Standby Equity Purchase Agreements and ATM Sales Agreement | 156 | 1,663 |
| Proceeds from issuance of Convertible Debentures | — | 9,600 |
| Proceeds from issuance of Revolving Facility | 32,567 | — |
| Repayment of Revolving Facility | (33,313) | — |
| Repayment of Oramed Note | (15,000) | — |
| Transaction costs paid related to the Business Combination | — | (634) |
| Repayment of Convertible Debentures | (4,375) | — |
| Proceeds from issuance of shares under Bought Deal Offering | 10,000 | |
| Payments of Bought Deal Offering issuance costs | (1,277) | — |
| Proceeds from stock options exercised | 46 | — |
| Net cash (used for) proceeds from financing activities | (11,196) | 10,629 |
| Net change in cash, cash equivalents and restricted cash | (1,955) | 2,885 |
| Cash, cash equivalents and restricted cash at beginning of period | 4,729 | 2,184 |
| Cash, cash equivalents and restricted cash at end of period | $2,774 | $5,069 |
| Supplemental disclosure: | ||
| Non-cash investing and financing activities | ||
| Issuance of shares to B. Riley pursuant to B. Riley Purchase Agreement | $— | $1,869 |
| Issuance costs related to Bought Deal Offering included in accrued expenses | $1,501 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.